Endocrine and lipid effects of oral L-arginine treatment in healthy postmenopausal women

Journal of Laboratory and Clinical Medicine

Volumn 135, Issue 3, 2000, Pages 231-237

  Blum, Arnon ^a,b   Cannon III, Richard O ^a   Costello, Rene ^a   Schenke, William H ^a   Csako, Gyorgy ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Poriya Hospital   (Israel)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034163564     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2000.104909     Document Type: Article

References (38)

1. 1. Guetta V, Quyyumi AA, Prasad A, Panza JA, Waclawiw M, Cannon RO III. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997;96:2795-801.
2. 2. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41.
3. 3. De Caterina R, Libby P, Peng HB, Thannickal VJ, RajarashisthTB, Gimbrone MA, et al. Nitric oxide decreases cytokine-induced activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-8.
4. 4. Sullivan JM, VanderZwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557-62.
5. 5. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1992;325:756-62.
6. 6. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogen and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
7. 7. Pilote L, Hlatky MA. Attitudes of women toward hormone replacement therapy and prevention of heart disease. Am Heart J 1995;129:1237-8.
8. 8. Palmer RM, Ashton DJ, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-6.
9. 9. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994;23:1121-31.
10. 10. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-53.
11. 11. Drexler H, Zeiher A, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patient by L-arginine. Lancet 1991;338:1546-50.
12. 12. Quyyumi AA, Dakak N, Diodati JG, Gilligan DM, Panza JA, Cannon RO III. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol 1997;30:1220-7.
13. 13. Giugliano D, Marfella R, Verrazzo G, Acampora R, Coppola L, Cozzolino D, et al. The vascular effects of L-arginine in humans. The role of endogenous insulin. J Clin Invest 1997;99:433-8.
14. 14. Cooke JP, Tsao PS. Arginine: a new therapy for atherosclerosis? Circulation 1997;95:311-2.
15. 15. Koppeschaar HP, ten Horn CD, Thijssen JH, Page MD, Dieguez C, Scanlon MF. Differential effects of arginine on growth hormone-releasing hormone and insulin-induced growth hormone secretion. Clin Endocrinol 1992;36:487-90.
16. 16. Isidori A, Lo Monaco A, Cappa M. A study of growth hormone release in man after oral administration of amino acids. Curr Med Res Opin 1981;7:475-81.
17. 17. Besset A, Bonardet A, Rondouin G, Descomps GB, Passouant P. Increases in sleep related GH and Pr secretion after chronic arginine aspartate administration in man. Acta Endocrinol 1982;99:18-23.
18. 18. Johannsson G, Oscarsson J, Rosen T, Wiklund O, Olsson G, Wilhelmsen L, et al. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and apo(a) and apo E phenotypes. Arterioscler Thromb Vasc Biol 1995;15:2142-50.
19. 19. O'Halloran DJ, Wieringa G, Tsatsoulis A, Shalet SM. Increased serum lipoprotein(a) concentrations after growth hormone (GH) in patients with isolated GH deficiency. Ann Clin Biochem 1996;33:330-4.
20. 20. Schlaich MP, John S, Langenfeld MR, Lackner KJ, Schmitz G, Schmieder RE. Does lipoprotein(a) impair endothelial function? J Am Coll Cardiol 1998;31:359-65.
21. 21. Schachinger V, Halle M, Minners J, Berg A, Zeiher AM. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 1997;30:927-34.
22. 22. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990;301:1248-51.
23. 23. Rhoads GG, Dahlen G, Berg K, Motion NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986;256:2540-4.
24. 24. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996;97:1989-94.
25. 25. Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996;93:2135-41.
26. 26. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-9.
27. 27. Bellone J, Bartolotta E, Cardinale G, Arvat E, Cherubini V, Aimaretti G, et al. Low dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children. J Endocrinol Invest 1993;16:521-5.
28. 28. Floyd JC Jr, Fajans SS, Conn JW, Knopf RF, Rull J. Stimulation of insulin secretion by amino acids. J Clin Invest 1966;45:1487-502.
29. 29. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981;30:219-25.
30. 30. Hwang IS, Huang WC, Wu JN, Shian LR, Reaven GM. Effect of fructose-induced hypertension on the renin-angiotensin-aldosterone system and arterial natriuretic factor. Am J Hypertens 1989;2:424-7.
31. 31. Christensen NJ. Acute effects of insulin on cardiovascular function and noradrenaline uptake and release. Diabetologia 1983;25:377-81.
32. 32. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;98:894-8.
33. 33. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993;13:296-301.
34. 34. Russell-Jones DL, Watts GF, Weissberger A, Naoumova R, Myers J, Thompson GR, et al. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Endocrinol 1994;41:345-50.
35. 35. Levine DM, Sloan B-J, Donner JE, Lorenz JD, Heinzerling RH. Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. Int J Clin Lab Res 1992;22:173-8.
36. 36. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995;41:246-55.
37. 37. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem 1991;266:2459-65.
38. 38. Newby DE, Wright RA, Dawson P, Ludlam CA, Boon NA, Fox KA, et al. The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res 1998;38:485-92.